Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Closes Labs, Focuses On New Medical Device

XTALKS VITALS NEWS

Elizabeth Holmes

As a result of the closures, Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona.

Tweetables from this article:

Tweet: #Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona http://ctt.ec/7u5lk+ Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona.

Share this!

October 7, 2016 | by Sarah Hand, M.Sc.

In a surprising turn, Theranos founder Elizabeth Holmes has announced the company will be shutting down clinical testing labs and consumer blood testing services, in order to focus on its recently-unveiled miniLab medical device. As a result of the closures, Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona.

Theranos’ novel blood testing technology has been the basis of the business since the beginning, but has recently faced controversy after the company voided thousands of test results in response to concerns over the technology’s accuracy. Amidst the controversy, Holmes received a 2 year ban from owning a blood testing laboratory from the Centers for Medicare & Medicaid Services (CMS).



“We will return our undivided attention to our miniLab platform,” said Holmes in an open letter on Theranos’ website. “Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.”

The letter also refers to a new executive team at Theranos, an announcement that follows COO and President Sunny Balwani’s decision to resign earlier this year. Holmes also vows to pursue FDA approval for the new device, along with publications in peer-reviewed journals. The company has previously faced scrutiny over failing to publish data from their Edison medical device.

Their next focus – the miniLab medical device – was announced in August at the American Association for Clinical Chemistry (AACC) conference. Holmes claims the device will be able to use multiple diagnostic methods to analyze a small-volume blood sample using a single device.

“We’re pleased to share our technologies with the entire laboratory industry,” Holmes said of the miniLab device. “It’s the beginning of the next phase of the company, as we introduce our technologies to the world. We also will be working with academic institutions and other independent parties to validate and publish our results.”


Keywords: Blood Testing, Medical Device, Clinical Laboratory


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.